Schneider National, Inc.

5. INVESTMENTS

Marketable Securities

Our marketable securities are classified as available-for-sale and carried at fair value in current assets on the consolidated balance sheets. While our intent is to hold our securities to maturity, sudden changes in the market or our liquidity needs may cause us to sell certain securities in advance of their maturity date.

Any unrealized gains and losses, net of tax, are included as a component of accumulated other comprehensive income on the consolidated balance sheets, unless we determine that the amortized cost basis is not recoverable. If we determine that the amortized cost basis of the impaired security is not recoverable, we recognize the credit loss by increasing the allowance for those losses. We didnot have an allowance for credit losses on our marketable securities as of March 31, 2025 or December 31, 2024. Cost basis is determined using the specific identification method.

The following table presents the remaining maturities and values of our marketable securities as of the dates shown.

Equity Investments without Readily Determinable Fair Values

The Company’s primary strategic equity investments without readily determinable fair values include Platform Science, Inc., a provider of telematics and fleet management tools, and MLSI, a transportation technology development company. The Company previously had an investment in ChemDirect, a business-to-business digital marketplace for the chemical industry. In February 2025, ChemDirect’s Board passed a resolution to dissolve the company. As a result, we recorded a $4.9 million loss in other expense—net on the consolidated statements of comprehensive income for the three months ended March 31, 2025. These investments are being accounted for under ASC 321, Investments - Equity Securities, using the measurement alternative, and their combined values as of March 31, 2025 and December 31, 2024 were $123.9 million and $124.4 million, respectively. If the Company identifies observable price changes for identical or similar securities of the same issuer, the equity security is measured at fair value as of the date the observable transaction occurred using Level 3 inputs. As of March 31, 2025, our cumulative upward and downward adjustments were $78.9 million and $4.9 million, respectively.

In addition to our investment in MLSI, we hold $23.0 million in notes receivable from MLSI as of March 31, 2025. We funded a $13.0 million note receivable in the first quarter of 2025 and a $10.0 million note receivable in the first quarter of 2023. The notes mature in May 2025 and March 2030, respectively, and are subject to interest over their respective terms. We also hold a $2.5 million note receivable from Platform Science, Inc. as of March 31, 2025. This note was executed and funded during the second quarter of 2024, is subject to interest over its term, and matures in March 2027.

The following table summarizes the activity related to these equity investments during the periods presented.

(1) Our updated investment value in 2025 related to Platform Science, Inc. and was determined using a combination of the discounted cash flow and guideline public company methods.

Equity Investments with Readily Determinable Fair Values

In 2021, the Company purchased a $5.0 million non-controlling interest in TuSimple, a global self-driving technology company. Upon completion of its IPO in April 2021, our investment in TuSimple was converted into Class A common shares and is being accounted for under ASC 321, Investments - Equity Securities. Our net investment and activity were not material for the three months ended March 31, 2025 and 2024. See Note 4, Fair Value, for additional information on the fair value of our investment in TuSimple.

Equity Method Investment

In the second quarter of 2023, the Company invested $5.0 million consisting primarily of internal use software and cash in exchange for a 50% non-controlling ownership interest in Scope 23 LLC, an entity that provides a platform for shippers to track and manage their greenhouse gas emissions. Our interest is being accounted for under ASC 323, Investments - Equity Method and Joint Ventures. For the three months ended March 31, 2025 and 2024, activity was not material. The carrying value of our investment was $4.4 million and $4.5 million as of March 31, 2025 and December 31, 2024, respectively.

All of our equity investments, our note receivable from Platform Science, Inc., and the $10.0 million note receivable from MLSI are included in internal use software and other noncurrent assets, while the $13.0 million note receivable from MLSI is current and included in other receivables on the consolidated balance sheets. Gains or losses on our equity investments are recognized within other expenses—net on the consolidated statements of comprehensive income.